DK3422845T3 - Gnavere med et humaniseret tmprss-gen - Google Patents

Gnavere med et humaniseret tmprss-gen Download PDF

Info

Publication number
DK3422845T3
DK3422845T3 DK17709888.6T DK17709888T DK3422845T3 DK 3422845 T3 DK3422845 T3 DK 3422845T3 DK 17709888 T DK17709888 T DK 17709888T DK 3422845 T3 DK3422845 T3 DK 3422845T3
Authority
DK
Denmark
Prior art keywords
gnager
tmprss gene
humanized tmprss
humanized
gene
Prior art date
Application number
DK17709888.6T
Other languages
English (en)
Inventor
Yajun Tang
Ngambo Lisa Purcell
Alexander O Mujica
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK3422845T3 publication Critical patent/DK3422845T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Environmental Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK17709888.6T 2016-02-29 2017-02-27 Gnavere med et humaniseret tmprss-gen DK3422845T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662301023P 2016-02-29 2016-02-29
PCT/US2017/019574 WO2017151453A1 (en) 2016-02-29 2017-02-27 Rodents having a humanized tmprss gene

Publications (1)

Publication Number Publication Date
DK3422845T3 true DK3422845T3 (da) 2021-08-30

Family

ID=58264641

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17709888.6T DK3422845T3 (da) 2016-02-29 2017-02-27 Gnavere med et humaniseret tmprss-gen

Country Status (14)

Country Link
US (5) US10070632B2 (da)
EP (2) EP3422845B1 (da)
JP (1) JP6980674B2 (da)
KR (2) KR102493894B1 (da)
CN (1) CN109068621B (da)
AU (1) AU2017228293B2 (da)
CA (1) CA3014645C (da)
DK (1) DK3422845T3 (da)
ES (1) ES2886958T3 (da)
IL (1) IL261139B (da)
PT (1) PT3422845T (da)
RU (1) RU2749715C2 (da)
SG (2) SG11201807038UA (da)
WO (1) WO2017151453A1 (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102493894B1 (ko) * 2016-02-29 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 인간화 tmprss 유전자를 갖는 설치류
EP4276185A3 (en) * 2017-09-29 2024-02-21 Regeneron Pharmaceuticals, Inc. Rodents comprising a humanized ttr locus and methods of use
MA46731B1 (fr) 2018-01-26 2021-06-30 Regeneron Pharma Anticorps anti-tmprss2 et fragments de liaison à l'antigène
CN116200426A (zh) 2018-07-16 2023-06-02 瑞泽恩制药公司 Ditra疾病的非人动物模型及其用途
MX2021008291A (es) 2019-01-17 2021-08-05 Regeneron Pharma Un modelo de roedor de trastornos del estado de animo.
AU2021219671A1 (en) 2020-02-10 2022-07-14 Regeneron Pharmaceuticals, Inc. Anti-Tmprss2 Antibodies and Antigen-Binding Fragments
CN115161326A (zh) * 2021-06-21 2022-10-11 百奥赛图(北京)医药科技股份有限公司 Sost基因人源化非人动物及其构建方法和应用
WO2023122506A1 (en) * 2021-12-20 2023-06-29 Regeneron Pharmaceuticals, Inc. Non-human animals comprising humanized ace2 and tmprss loci

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002065266A (ja) * 2000-08-28 2002-03-05 Teijin Ltd 気道特異的トリプシン様酵素およびその利用法
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7479579B2 (en) * 2001-12-20 2009-01-20 The Regents Of The University Of California Triple transgenic mouse model of Alzheimer's disease
US20050026255A1 (en) * 2002-06-25 2005-02-03 Morser John Michael Corin, a serine protease
EP1558731A4 (en) * 2002-10-04 2007-01-10 Schering Ag MODIFIED HEPSINE MOLECULES COMPRISING A SUBSTITUTION ACTIVATION SEQUENCE AND USES THEREOF
RU2006100035A (ru) * 2003-06-11 2006-08-27 Шеринг Акциенгезельшафт (De) Новые модифицированные кориновые молекулы, имеющие замещенные активирующие последовательности, и их применение
US7491865B2 (en) * 2004-08-19 2009-02-17 Fred Hutchinson Cancer Research Center Mouse models of prostate cancer development and metastasis through expression of a hepsin transgene
ES2667169T3 (es) 2004-10-19 2018-05-09 Regeneron Pharmaceuticals, Inc. Método para generar un animal no humano homocigótico para una modificación genética
CA2651043A1 (en) * 2006-05-23 2007-12-06 David C. Tully Compounds and compositions as channel activating protease inhibitors
GB0821624D0 (en) * 2008-11-26 2008-12-31 Eisai London Res Lab Ltd Assay
JP5851842B2 (ja) * 2009-01-12 2016-02-03 サイトムエックス セラピューティクス, インク.CytomX Therapeutics, Inc. 改変した抗体組成物、それを作製および使用する方法
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
ES2908587T3 (es) 2009-10-06 2022-05-03 Regeneron Pharma Ratones modificados genéticamente e injerto
DK3375284T3 (da) * 2011-02-15 2023-06-12 Univ Yale Humaniserede M-CSF-mus og anvendelser deraf
SI2770821T1 (en) 2011-10-28 2018-01-31 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex of mice
HUE048511T2 (hu) 2011-10-28 2020-07-28 Regeneron Pharma Kiméra fõ hisztokompatibilitási komplex (MHC) II molekulákat expresszáló, genetikailag módosított egerek
SG10201600965YA (en) 2011-10-28 2016-03-30 Regeneron Pharma Humanized il-6 and il-6 receptor
BR112014025339A8 (pt) * 2012-04-16 2018-01-16 Regeneron Pharma método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo.
US8962913B2 (en) 2012-06-18 2015-02-24 Regeneron Pharmaceuticals, Inc. Humanized IL-7 rodents
PE20150643A1 (es) * 2012-06-22 2015-05-29 Cytomx Therapeutics Inc Anticuerpos de reaccion cruzada anti-jagged 1/jagged 2 anticuerpos anti-jagged activables y metodos de uso de los mismos
EP4193834A1 (en) 2012-09-07 2023-06-14 Yale University Genetically modified non-human animals and methods of use thereof
EP3556206B1 (en) 2012-11-05 2021-06-02 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals and methods of use thereof
HUE045478T2 (hu) 2013-02-20 2019-12-30 Regeneron Pharma Humanizált T-sejt koreceptorokat expresszáló egerek
EP2958990B1 (en) 2013-02-20 2019-10-16 Regeneron Pharmaceuticals, Inc. Genetic modification of rats
JP6444321B2 (ja) 2013-02-22 2018-12-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化主要組織適合性遺伝子複合体を発現するマウス
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
HUE040575T2 (hu) 2013-04-16 2019-03-28 Regeneron Pharma A patkány genom célzott módosítása
CA2913732A1 (en) 2013-06-04 2014-12-11 Cytomx Therapeutics, Inc. Compositions and methods for conjugating activatable antibodies
RS64573B1 (sr) 2013-09-23 2023-10-31 Regeneron Pharma Ne-humana životinja sa humanizovanim signalno-regulatornim proteinskim genom
SI3138397T1 (sl) 2013-10-15 2019-04-30 Regeneron Pharmaceuticals, Inc. Humanizirane živali IL-15
JP6484237B2 (ja) 2013-11-19 2019-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ヒト化増殖誘導リガンド遺伝子を有する非ヒト動物
WO2015077071A1 (en) 2013-11-19 2015-05-28 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
NO2785538T3 (da) 2014-05-07 2018-08-04
DK3841877T3 (da) 2014-05-19 2023-11-27 Regeneron Pharma Genetisk modificeret mus, der eksprimerer human EPO
RU2735958C2 (ru) 2014-06-19 2020-11-11 Регенерон Фармасьютикалз, Инк. Животные, отличные от человека, имеющие гуманизированный ген 1 запрограммированной гибели клеток
RU2020122439A (ru) 2014-11-24 2020-09-24 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, экспрессирующие гуманизированный комплекс cd3
US20160345549A1 (en) 2014-12-05 2016-12-01 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized cluster of differentiation 47 gene
PT3230320T (pt) 2014-12-09 2021-01-08 Regeneron Pharma Animais não humanos tendo um gene do cluster humanizado de diferenciação 274
HRP20231039T1 (hr) 2015-04-06 2023-12-22 Regeneron Pharmaceuticals, Inc. Imunosni odgovori posredovani humaniziranim t stanicama kod ne-humanih životinja
KR102454546B1 (ko) 2015-11-20 2022-10-14 리제너론 파마슈티칼스 인코포레이티드 인간화 림프구 활성화 유전자 3을 갖는 비인간 동물
KR102493894B1 (ko) 2016-02-29 2023-01-31 리제너론 파마슈티칼스 인코포레이티드 인간화 tmprss 유전자를 갖는 설치류
KR101693243B1 (ko) * 2016-06-15 2017-01-05 재단법인 한국파스퇴르연구소 인플루엔자 바이러스의 복제에 관여하는 신규 인간 유전자 및 이의 용도

Also Published As

Publication number Publication date
EP3895529A1 (en) 2021-10-20
US20240147971A1 (en) 2024-05-09
RU2018131152A3 (da) 2020-07-13
ES2886958T3 (es) 2021-12-21
RU2018131152A (ru) 2020-04-01
AU2017228293A1 (en) 2018-08-23
US20170290308A1 (en) 2017-10-12
SG10202001578RA (en) 2020-04-29
IL261139A (en) 2018-10-31
WO2017151453A1 (en) 2017-09-08
CN109068621B (zh) 2021-07-20
JP6980674B2 (ja) 2021-12-15
SG11201807038UA (en) 2018-09-27
IL261139B (en) 2022-04-01
US20180332831A1 (en) 2018-11-22
CA3014645C (en) 2022-10-25
PT3422845T (pt) 2021-08-26
US10863729B2 (en) 2020-12-15
KR20180117122A (ko) 2018-10-26
US20170245482A1 (en) 2017-08-31
KR102493894B1 (ko) 2023-01-31
US10070631B2 (en) 2018-09-11
EP3422845A1 (en) 2019-01-09
US11910787B2 (en) 2024-02-27
CA3014645A1 (en) 2017-09-08
US20210068377A1 (en) 2021-03-11
JP2019511918A (ja) 2019-05-09
US10070632B2 (en) 2018-09-11
EP3422845B1 (en) 2021-06-02
RU2749715C2 (ru) 2021-06-16
AU2017228293B2 (en) 2023-05-25
KR20230021759A (ko) 2023-02-14
CN109068621A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
NL301117I1 (nl) trastuzumab deruxtecan
DK3422845T3 (da) Gnavere med et humaniseret tmprss-gen
DK3560954T3 (da) Modificeret j-kæde
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3558995T3 (da) Polymorfer
DK3558961T3 (da) Polymorfer
MA46285A (fr) Polythérapie
MA51576A (fr) Polythérapie
ES1123386Y (es) Un quitasol
DK3164367T3 (da) Udglatning af en coating
DK3308018T3 (da) Drivanordning
ITUB20155097A1 (it) Anticorpi umanizzati anti-BAG3
DK3188963T3 (da) Forbedring af en skrue
DE112015002630A5 (de) Rollenelement
FR3046841B1 (fr) Couplemetre a torsion
DK3394653T3 (da) Plenoptisk zoom med optimeret rækkevidde
DK3169346T3 (da) Antiinflammatoriske egenskaber af et overfladeprotein af propionibakterie freudenreichii
FR3025894B1 (fr) Miroir a durabilite amelioree
MA46201A (fr) Un linteau
DE102016105487A8 (de) Wellschlauch mit einem haltering
DK3112579T3 (da) En stige
DK3231806T3 (da) Fremgangsmåder til fremstilling af penamer
DE112014006602A5 (de) Positioniersystem
FR3034118B1 (fr) Tuile a emboitement
DE112015002871A5 (de) Positionssensitives optisches Element